Radius Health
Focus: Radius Health is a publicly traded biotechnology company headquartered in Boston focused on small molecules and biologics in endocrinology and oncology. The company derives 100% of revenue from its flagship osteoporosis drug TYMLOS (abaloparatide).
Profile data last refreshed 18h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Radius Health
AI assessmentNot HiringNo open roles listed right now. Follow Radius Health to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$198M (Part D)Stable
Peak13.4yr
Flagship revenue driver with 16-year LOE runway; all company value hinges on sustained market share in postmenopausal osteoporosis.
Help build intelligence for Radius Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.